Advertisement

Engraftment-Promoting Potential of High-Dose Cytostatic Agents in Allogeneic Bone Marrow Transplantation

  • B. Glass
  • W. Gassmann
  • L. Uharek
  • A. Erbersdobler
  • H. Loeffler
  • W. Mueller-Ruchholtz
Conference paper
Part of the Haematology and Blood Transfusion / Hämatologie und Bluttransfusion book series (HAEMATOLOGY, volume 34)

Abstract

Graft rejection is a serious problem in HLA-mismatched and in T-cell-depleted HLA-identical bone marrow transplantation. Rejection rates of up to 35% have been observed in cases where HLA-identical hone marrow depleted of T lymphocytes was grafted following conventional conditioning with cyclophosphamide and total body irradiation [1].

Keywords

Rejection Rate Total Body Irradiation Allogeneic Bone Marrow Autologous Bone Marrow Transplantation Cytostatic Agent 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Patterson J, Prentice HG. Brenner MK, Gilmore M, Janossy G, Ivory K. Skeggs D. Morgan H, Lord J, Blacklock HA, Hoff-brand AV, Apperley JF, Goldman JM, Burnett A, Gribben A, Alcorn M, Pearson C, Mcvickers I, Hann IM, Reid C, Wardle D, Gravett PJ, Bacigalupo A, Robertson AG (1986) Graft rejection following HLS matched T-lymphocyte depleted bone marrow transplantation. BR J Haematol 63: 221–230PubMedCrossRefGoogle Scholar
  2. 2.
    Tutschka PJ, Santos GW (1975) Bone marrow transplantation in the busulfan-treated rat. Transplantation 20: 101–106PubMedCrossRefGoogle Scholar
  3. 3.
    Harada M,YoshidaT, Funada H. Hattori K-I for the Kanazawa University Bone Marrow Transplant Team (1984) Clinical trial of intensive therapy and autologous bone marrow transplantation in the treatment of malignant diseases. Jpn J Clin Oncol 14 [Suppl 11: 543–552Google Scholar
  4. 4.
    Carella AM. Congiu AM. Gaozza E, Ricci P, Visani G, Meloni G, Cimino G, Mangoni L, Coser P. Cetto GL, Cimino R, Alessandrio EP, Brusamolino E, Santini G, Tura S, Mandelli E Rizzoli V. Bernasconi C, Marmont AM (1988) High-dose chemotherapy with autologous bone marrow transplantation in 50 advanced Hodgkin’s disease patients: an Italian study group report. J Clin Oncol 6: 1411–1416PubMedGoogle Scholar
  5. 5.
    Lazarus HM, Reed MD, Spitzer TR, Rabaa MS, Blumer JL (1987) High-dose iv thiotepa and cryopreserved autologous bone marrow transplantation for therapy of refractory cancer. Cancer Treat Rep 71: 689–695PubMedGoogle Scholar
  6. 6.
    Powles RL, Milliken S, Helenglass G, Trelcavan J, Pinkerton R, Zuiable A, Nandi A, Aboud H, Millar J (1989) The use of melphalan in conjunction with total body irradiation as treatment for acute leukaemia. Transplant Proc 21: 2955–2957PubMedGoogle Scholar
  7. 7.
    Nichols CR, Tricot G, Williams SD, van Besien K, Lochrer PJ, Roth BJ, Akard L, Hoffman R, Goulet R, Wolff SN, Gianonne L, Greer J, Einhorn LH, Jansen J (1989) Dose-intensive chemotherapy in refractory germ cell cancer — a phase I/II trial of high-dose carboplatin and etoposide with autologous bone marrow transplantation. J Clin Oncol 7: 932–939PubMedGoogle Scholar
  8. 8.
    Shea TC, Flaherty M, Elias A, Eder JP, Antman K, Begg C. Schnipper L, Frei EIII, Henner WD (1989) A phase I clinical and pharmacokinetic study of carboplatin and autologous bone marrow support. J Clin Oncol 7: 651–661PubMedGoogle Scholar
  9. 9.
    Gassmann W, Uharek L, Wottge HU, Schmitz N, Loeffler H, Mueller-Ruchholtz W (1988) Comparison of cyclophosphamide, cytarabine, and etoposide as immunosuppressive agents before allogeneic bone marrow transplantation. Blood 72: 1574–1579PubMedGoogle Scholar
  10. 10.
    Schmitz N, Gassmann W, Rister M, Johann-son W, Suttorp M. Brix F, Holthuis JJ, Heit W, Hcrtenstein B, Schaub J, Loeffler H (1988) Fractionated total body irradiation and high-dose VP 16–213 followed by allogeneic bone marrow transplantation in advanced leukemias. Blood 72: 1567–1573PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1992

Authors and Affiliations

  • B. Glass
    • 1
  • W. Gassmann
    • 1
  • L. Uharek
    • 1
  • A. Erbersdobler
    • 1
  • H. Loeffler
    • 1
  • W. Mueller-Ruchholtz
    • 1
  1. 1.Second Department of Internal Medicine and Department of ImmunologyUniversity of KielKielGermany

Personalised recommendations